▸ 2 Oct 2026, 09:41 Galidesivir GMP manufacturing commences Company Update
▸ 30 Sep 2026, 11:53 Annual General Meeting - Rescheduled Date Meetings & Governance
▸ 31 Aug 2026, 09:01 Pivotal Marburg data secured for Galidesivir FDA pathway Company Update
▸ 26 Aug 2026, 15:16 Appendix 4G and Corporate Governance Statement Company Administration
▸ 26 Aug 2026, 15:16 Annual Report to shareholders Financial Results
▸ 26 Aug 2026, 15:04 Preliminary Final Report Financial Results
▸ 21 Aug 2026, 08:56 Island boosts Galidesivir supply as Ebola surges Company Update
▸ 13 Aug 2026, 09:21 Date of AGM & Closing Date for Director Nominations Meetings & Governance
▸ 12 Aug 2026, 09:35 Cleansing Notice Securities Administration
▸ 12 Aug 2026, 09:32 Application for quotation of securities - ILA Securities Administration
▸ 7 Aug 2026, 08:43 Investor presentation Presentations
▸ 30 Jul 2026, 09:47 Quarterly Appendix 4C and Activities Report Quarterly Reports
▸ 27 Jul 2026, 09:23 Investor Presentation - TechKnow Invest Roadshow Presentations
▸ 13 Jul 2026, 16:29 Notification regarding unquoted securities - ILA Securities Administration
▸ 13 Jul 2026, 16:27 Notification regarding unquoted securities - ILA Securities Administration
▸ 13 Jul 2026, 16:21 Notification regarding unquoted securities - ILA Securities Administration
▸ 13 Jul 2026, 16:21 Notification regarding unquoted securities - ILA Securities Administration
▸ 13 Jul 2026, 09:46 Texas Biomed SOW accelerates pivotal FDA pathway Company Update
▸ 8 Jul 2026, 10:02 Investor Presentation - Ebola Clinical Program Presentations
▸ 8 Jul 2026, 09:00 Notification of cessation of securities - ILA Securities Administration
▸ 7 Jul 2026, 09:02 Galidesivir approved for treatment use in in Ebola epidemic Company Update
▸ 3 Jul 2026, 12:23 Trading Halt Trading Halt / Suspension
▸ 3 Jul 2026, 12:01 Pause in Trading Trading Halt / Suspension
▸ 2 Jul 2026, 09:38 Singapore Patent Expands Island's ISLA 101 Viral Protection Company Update
▸ 17 Jun 2026, 08:54 FDA Grants Orphan Designation for Galidesivir in Marburg Company Update
▸ 16 Jun 2026, 09:58 Investor Presentation - Asia Dengue Summit Presentations
▸ 11 Jun 2026, 12:25 Investor presentation (updated) Presentations
▸ 11 Jun 2026, 09:46 Investor presentation Presentations
▸ 10 Jun 2026, 08:53 Island Secures USAMRIID Support for Galidesivir Study Company Update
▸ 4 Jun 2026, 09:03 Island Advances Galidesivir GMP Manufacturing for Biodefence Company Update
▸ 21 May 2026, 09:25 Island Adds Biodefence Leader as Filovirus Risks Escalate Company Administration
▸ 19 May 2026, 08:44 Island Bolsters US Biodefence Readiness Ahead of Trials Company Update
▸ 28 Apr 2026, 08:30 Cleansing Notice Securities Administration
▸ 28 Apr 2026, 08:23 Application for quotation of securities - ILA Securities Administration
▸ 27 Apr 2026, 09:46 Quarterly Appendix 4C and Activities Report Quarterly Reports
▸ 30 Mar 2026, 11:19 Cleansing Notice Securities Administration
▸ 30 Mar 2026, 11:17 Application for quotation of securities - ILA Securities Administration
▸ 23 Mar 2026, 10:29 Cleansing Notice Securities Administration
▸ 23 Mar 2026, 10:27 Application for quotation of securities - ILA Securities Administration
▸ 9 Mar 2026, 09:47 Antiviral pipeline expansion through strategic collaboration Company Update
▸ 4 Mar 2026, 09:22 US Government collaboration for Galidesivir development Company Update
▸ 2 Mar 2026, 09:37 Trading Halt Trading Halt / Suspension
▸ 25 Feb 2026, 16:21 Appendix 4D & Half-Year Financial Statements Financial Results
▸ 16 Feb 2026, 08:28 Cleansing Notice Securities Administration
▸ 16 Feb 2026, 08:21 Application for quotation of securities - ILA Securities Administration
▸ 10 Feb 2026, 10:45 Response to ASX Query Letter ASX Query
▸ 5 Feb 2026, 09:57 Investor presentation Presentations
▸ 4 Feb 2026, 09:34 Proposed issue of securities - ILA Securities Administration
▸ 4 Feb 2026, 09:34 $9m placement to advance US biodefence opportunity Capital Raising
▸ 4 Feb 2026, 09:29 FDA confirms Galidesivir approval pathway Company Update
▸ 2 Feb 2026, 08:43 Trading Halt Trading Halt / Suspension
▸ 27 Jan 2026, 08:33 Investor Presentation Presentations
▸ 27 Jan 2026, 08:32 Quarterly Appendix 4C and Activities Report Quarterly Reports
▸ 7 Jan 2026, 09:44 US Patent Granted for Galidesivir in filoviridae viruses Company Update
▸ 6 Jan 2026, 09:40 Notification regarding unquoted securities - ILA Securities Administration
▸ 5 Jan 2026, 08:41 Ongoing engagement with the US FDA Company Update
▸ 17 Dec 2025, 08:36 Agreement with Texas Biomed for Galidesivir Program Company Update
▸ 9 Dec 2025, 12:14 Change in substantial holding Substantial Holders
▸ 9 Dec 2025, 12:12 Change in substantial holding Substantial Holders
▸ 9 Dec 2025, 12:08 Change in substantial holding Substantial Holders
▸ 5 Dec 2025, 09:52 Island expands Galidesivir IP with US Patent Grant Company Update
▸ 4 Dec 2025, 08:27 Additional FDA Submission completed for Galidesivir Company Administration
▸ 3 Dec 2025, 17:06 Change of Director's Interest Notice - CN & JC Director Interests
▸ 3 Dec 2025, 08:37 Options exercised raises $1million Securities Administration
▸ 3 Dec 2025, 08:32 Cleansing Notice Securities Administration
▸ 3 Dec 2025, 08:30 Application for quotation of securities - ILA Securities Administration
▸ 24 Nov 2025, 08:43 Coalition acceptance to advance US procurement & stockpiling Company Update
▸ 20 Nov 2025, 09:34 Island engages advisers to advance biodefence strategy Company Update
▸ 17 Nov 2025, 09:27 FDA agrees Animal Rule pathway and PRV eligibility Company Update
▸ 14 Nov 2025, 08:53 Change of registered address Securities Administration
▸ 13 Nov 2025, 14:34 Webinar - FDA response to Galidesivir program Company Administration
▸ 13 Nov 2025, 09:12 Trading Halt Trading Halt / Suspension
▸ 13 Nov 2025, 08:30 Change of Director's Interest Notice - DF, JC & CN Director Interests
▸ 13 Nov 2025, 08:24 Notification regarding unquoted securities - ILA Securities Administration
▸ 5 Nov 2025, 09:10 Change of Director's Interest Notice - CN Director Interests
▸ 5 Nov 2025, 09:07 Change of Director's Interest Notice - DF Director Interests
▸ 30 Oct 2025, 09:11 Cleansing Notice Securities Administration
▸ 30 Oct 2025, 09:09 Application for quotation of securities - ILA Securities Administration
▸ 30 Oct 2025, 09:02 Quarterly Appendix 4C and Activities Report Quarterly Reports
▸ 22 Oct 2025, 09:33 FDA confirms response timing for Galidesivir Company Update
▸ 17 Oct 2025, 09:13 Cleansing Notice Securities Administration
▸ 17 Oct 2025, 09:10 Application for quotation of securities - ILA Securities Administration
▸ 9 Oct 2025, 13:24 Results of AGM Meetings & Governance
▸ 3 Oct 2025, 08:46 Notification regarding unquoted securities - ILA Securities Administration
▸ 29 Sep 2025, 08:29 US FDA Type C meeting briefing document submitted Company Update
▸ 19 Sep 2025, 09:29 FDA Meeting request granted Company Update
▸ 18 Sep 2025, 09:06 Investor webinar Presentations
▸ 17 Sep 2025, 09:53 Investor presentation - Galidesivir update Presentations
▸ 9 Sep 2025, 08:29 Cleansing Notice Securities Administration
▸ 9 Sep 2025, 08:29 Application for quotation of securities - ILA Securities Administration
▸ 5 Sep 2025, 09:44 Letter to Shareholders, Notice of AGM & Proxy Form Presentations
▸ 1 Sep 2025, 08:45 FDA meeting request lodged for Galidesivir Company Update
▸ 29 Aug 2025, 10:09 Annual Report to shareholders (incl auditor independence) Financial Results
▸ 29 Aug 2025, 08:27 Appendix 4G and Corporate Governance Statement Company Administration
▸ 29 Aug 2025, 08:25 Annual Report to shareholders Financial Results
▸ 29 Aug 2025, 08:22 Preliminary Final Report Financial Results
▸ 15 Aug 2025, 10:07 Change in substantial holding Substantial Holders
▸ 14 Aug 2025, 12:08 Date of AGM & Closing Date for Director Nominations Meetings & Governance
▸ 14 Aug 2025, 09:32 Presentation to the Third Annual Dengue Endgame Summit Presentations
▸ 11 Aug 2025, 09:55 Options exercise from existing substantial shareholder Securities Administration